Vatti R, Sharma O P
Division of Pulmonary and Critical Care Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA.
Sarcoidosis Vasc Diffuse Lung Dis. 1997 Mar;14(1):73-6.
Although granulomatous involvement of the liver with functional abnormalities is widely known, the course of these abnormalities is not clearly known. The study was designed to find out the incidence and course of asymptomatic liver function abnormalities.
From 1990-1995, during the five year period, 44 (35.2%) of 125 patients with sarcoidosis at LAC + USC Medical Center had liver involvement. Liver enzyme abnormalities aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (AP) were taken as criteria for liver involvement: 41 (93%) patients had elevated AP, 22 (50%) showed elevated ALT, and 24 (54.5%) had elevated AST.
25 of 44 patients received treatment; 12 (48%) showed improvement in liver enzymes and 13 (52%) remained unchanged. Ten (7%) of 13 patients, who did not receive any treatment, also improved. During the same period at USC University Hospital 18 (25%) of 72 had liver involvement. Twelve patients received treatment; 6 (50%) patients showed improvement in liver enzymes. One of 3 patients, who did not receive treatment, improved. 5 (41%) developed complications due to steroids.
Liver involvement is common in African American patients with sarcoidosis. Social and economic status do not seem to influence the liver involvement. In men the age distribution has an early peak. The outcome of patients who receive treatment remains similar, as far as liver function is concerned, suggesting that most of the patients with liver involvement undergo natural remission. Unless the patient has progressive liver dysfunction, it is advisable to monitor liver enzymes periodically and obtain liver biopsies only if clinically indicated. In patients who need treatment, it is reasonable to try options other than steroids in view of severe corticosteroid related complications.
尽管肝脏肉芽肿性病变伴功能异常已广为人知,但其异常过程尚不清楚。本研究旨在查明无症状肝功能异常的发生率和病程。
1990年至1995年这五年间,洛杉矶县+南加州大学医学中心125例结节病患者中有44例(35.2%)出现肝脏受累。将肝酶异常,即天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和碱性磷酸酶(AP)作为肝脏受累的标准:41例(93%)患者AP升高,22例(50%)ALT升高,24例(54.5%)AST升高。
44例患者中有25例接受了治疗;12例(48%)肝酶有所改善,13例(52%)保持不变。13例未接受任何治疗的患者中有10例(7%)也有所改善。同期,南加州大学医院72例患者中有18例(25%)出现肝脏受累。12例患者接受了治疗;6例(50%)患者肝酶有所改善。3例未接受治疗的患者中有1例有所改善。5例(41%)因使用类固醇出现并发症。
非裔美国结节病患者肝脏受累较为常见。社会和经济状况似乎不影响肝脏受累情况。男性患者的年龄分布有一个早期高峰。就肝功能而言,接受治疗的患者的结果相似,这表明大多数肝脏受累患者会自然缓解。除非患者有进行性肝功能障碍,建议定期监测肝酶,仅在临床有指征时进行肝活检。鉴于与皮质类固醇相关的严重并发症,对于需要治疗的患者,尝试使用类固醇以外的其他治疗方法是合理的。